Free tool · No account
Clinical trials for bladder cancer
Bladder cancer trials differ between early, non-muscle-invasive disease and advanced disease, with immunotherapy and antibody-drug conjugates prominent in the advanced setting.
509 recruiting trials. Showing a sample.
- recruitingPhase 2NCT06663137
A Study to Evaluate the Safety and Efficacy of NDV-01 in Participants With NMIBC
This is a prospective, single-arm study evaluating the safety and efficacy of NDV01 KIT, a fixed-dose combination of gemcitabine HCl and docetaxel, administered via intravesical instillation in patients with high-grade Non-Muscle Invasive Bladder Cancer (NMIBC). NDV01 KIT incl...
Listed by the study for Non Muscle Invasive Bladder Cancer. Record updated 2026-09-02.
Sponsored by Relmada Therapeutics, Inc.Full details on ClinicalTrials.gov → - recruitingPhase 1NCT06910657
IDOV-Immune for Advanced Solid Tumors
This is a Phase I clinical trial evaluating an investigational treatment called IDOV-Immune, a type of oncolytic virus therapy, for adults with advanced solid tumors that have not responded to standard treatments. Oncolytic viruses are designed to infect and destroy cancer cel...
Listed by the study for Bladder Cancer. Record updated 2026-08-05.
Sponsored by ViroMissile, Inc.Full details on ClinicalTrials.gov → - recruitingPhase 2NCT06809140
Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Bladder Cancer
Patients with MIBC will receive 3 cycles (C1-C3) of induction enfortumab vedotin plus pembrolizumab followed by restaging including MRI of the bladder, urine cytology, and cystoscopy with TURBT of any visible tumor and/or resection site plus random biopsies using a recommended...
Listed by the study for Muscle Invasive Bladder Urothelial Carcinoma. Record updated 2026-08-05.
Sponsored by Matthew GalskyFull details on ClinicalTrials.gov → - recruitingNCT04503577
Prospective Bladder Cancer Infrastructure (ProBCI)
Prospective nation-wide cohort of high-risk non-muscle-invasive, muscle-invasive and metastatic bladder cancer in the Netherlands
Listed by the study for Bladder Cancer. Record updated 2026-09-21.
Sponsored by Prospective Bladder Cancer Infrastructure FoundationFull details on ClinicalTrials.gov → - recruitingPhase 1NCT04878029
Cabozantinib in Combination With Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer
This phase I/Ib trial seeks to find out the best dose, possible benefits and/or side effects of cabozantinib in combination with enfortumab vedotin in treating urothelial cancer that has spread to nearby tissues and lymph nodes (locally advanced) or other parts of the body (me...
Listed by the study for Infiltrating Bladder Urothelial Carcinoma With Squamous Differentiation. Record updated 2026-04-29.
Sponsored by Emory UniversityFull details on ClinicalTrials.gov → - recruitingNCT04564781
Predicting BCG Response
To date, there are no diagnostics capable of predicting treatment response to intravesical BCG. Because of this severe limitation, nearly 50% of patients treated with BCG fail therapy and will a) require additional intravesical therapy or b) require cystectomy. A urine-based d...
Listed by the study for Bladder Cancer. Record updated 2026-07-06.
Sponsored by Cedars-Sinai Medical CenterFull details on ClinicalTrials.gov → - recruitingNANCT07495072
Early vs Delayed Intravesical Blad-Care During BCG Therapy
Intravesical Bacillus Calmette-Guérin (BCG) therapy is the standard adjuvant treatment for patients with intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC). However, BCG therapy frequently induces local bladder irritation symptoms including urinary frequenc...
Listed by the study for Urinary Bladder Neoplasms. Record updated 2026-03-27.
Sponsored by BLAD-HYA GroupFull details on ClinicalTrials.gov → - recruitingNANCT05321316
Nectin-4 Specific LMW PET Probe Imaging in Urothelial Carcinoma
To evaluate the ability of \[68Ga\]N188 to detect nectin-4 overexpression in patients with urothelial carcinoma, especially in patients with recurrent or advanced bladder cancer.
Listed by the study for Urothelial Carcinoma. Record updated 2026-03-04.
Sponsored by Peking University Cancer Hospital & InstituteFull details on ClinicalTrials.gov → - recruitingNANCT07728474
LCS103 Herbal Formula for Secondary Prevention of Non-Muscle Invasive Urothelial Carcinoma of the Bladder
This study is a phase IIA, single-site, randomized, controlled, open-label clinical trial evaluating the safety and efficacy of the LCS103 oral herbal formula for the secondary prevention of NMIBC. The study will include 60 participants randomized 1:1 to either the investigati...
Listed by the study for Non-muscle Invasive Bladder Cancer (NMIBC). Record updated 2026-07-29.
Sponsored by LifeBiotic Medical Research Ltd.Full details on ClinicalTrials.gov → - recruitingNCT05231655
Ex VIvo DEtermiNed Cancer Therapy
EVIDENT's aim is to test if ex vivo drug screening can predict whether patients with solid cancers will respond, or not respond, to standard care treatments. Patients undergoing standard care surgery to excise their tumour, those undergoing a biopsy, or those having a fluid as...
Listed by the study for Bladder Cancer. Record updated 2025-02-24.
Sponsored by Sheffield Teaching Hospitals NHS Foundation TrustFull details on ClinicalTrials.gov →
Data from ClinicalTrials.gov, retrieved 2026-10-12. Study sponsors write and update their own records there, including the recruitment status shown here, and the U.S. government does not review or approve every study listed. A trial showing up here is not a recommendation and not a determination that anyone qualifies. Eligibility is decided by the trial's own doctors.
Refine for your situation
Add whatever you know: an age, a city, a mutation from a pathology report. We'll narrow the list to trials that fit. Describe it in your own words.
Trials for other conditions
What we will never do with your records
This generator runs without an account, and KeptWell itself makes the same promises to every family, regardless of plan or price.
- We won't sell your data.
- Not to advertisers, not to data brokers, not to insurers, not to pharma, not to anyone, in any form, ever.
- We won't train AI models on your records.
- KeptWell does not opt in to model training. OpenAI and Anthropic do not use API inputs or outputs to train their models by default.
- We won't lock you in.
- You can export everything in your circle as a ZIP at any time. Cancellation is one click.
Common questions
- Is this bladder cancer trial finder really free?
- Yes. You describe the situation, we search ClinicalTrials.gov and show what matches. No account, no payment, no email required. Nothing you type is saved.
- Does showing up here mean the patient qualifies?
- No. A listing here is not a recommendation, and the U.S. government does not review or approve every study on ClinicalTrials.gov. These are trials worth asking your care team about. Every trial has detailed eligibility criteria that the trial's own doctors evaluate, and many depend on test results and treatment history that only your medical team knows in full.
- How current is this list?
- The trials come directly from ClinicalTrials.gov and are refreshed daily, with the retrieval date shown under the list. Each study record is written and kept up to date by that study's own sponsor, so the recruitment status is what the sponsor last reported. Each result links to the full, live record, and the finder above always runs a fresh search when you use it.
- What should I do with a trial that looks promising?
- Bring it to your oncologist or care team, and mention the NCT number (the ID that starts with NCT). They can tell you whether it is a genuine fit and refer you to the trial site.
Found trials worth discussing? Keep them next to the records.
The next step is a conversation with the care team, and that goes better when the scans, labs, and trial details live in one place everyone in the family can see. That's what KeptWell is: the binder, but it understands what's inside.
Get started
We'll email you a secure sign-in link. It works whether you're new here or already have an account.